Drug Trial Radar · NCT03695185
A Study to Investigate How Well Ravagalimab (ABBV-323) Works and How Safe it is in Participants With Moderate to Severe Ulcerative Colitis Who Failed Prior Therapy
Last checked: Nov 19, 2026Latest source record: Mar 15, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
42
Actual
Start
Mar 26, 2019
Primary completion
Apr 5, 2021
Study completion Jan 10, 2022
Sponsor
- Lead sponsor
- AbbVieAbbVie (ABBV)
- Sponsor type
- Industry
- First posted
- Oct 4, 2018
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Study M15-722 is a Phase 2a study to investigate the efficacy and safety of Ravagalimab (ABBV-323) in participants with moderate to severe UC who failed prior therapy.
Conditions
- Ulcerative Colitis (UC)
Interventions
Ravagalimab 600 mgDrug
Ravagalimab 600 mg was administered intravenously (IV).
Ravagalimab 300 mgDrug
Ravagalimab 300 mg was administered subcutaneously (SC).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With Endoscopic Improvement During Induction PeriodTime frame: At Week 8
Locations
34 sites in 10 countries. Site status is shown where the registry gives one.
Banner University Medical Cent /ID# 208392
Tucson, Arizona
Meridian Investigator Network /ID# 204646
Huntington Beach, California
Meridian Investigator Network /ID# 218568
Lakewood, California
TLC Clinical Research Inc /ID# 206626
Los Angeles, California
Orange County Institute of Gastroenterology and Endoscopy /ID# 207405
Mission Viejo, California
UC Davis Medical Center /ID# 209402
Sacramento, California
The University of Chicago DCAM /ID# 207086
Chicago, Illinois
Affinity Clinical Research /ID# 206211
Oak Brook, Illinois
Univ New Mexico /ID# 208817
Albuquerque, New Mexico
Penn Presbyterian Medical Center /ID# 206826
Philadelphia, Pennsylvania
Vanderbilt University Medical Center /ID# 204670
Nashville, Tennessee
Clinical Associates in Research Therapeutics of America, LLC /ID# 204689
San Antonio, Texas
Mount Sinai Hospital /ID# 206180
Toronto, Ontario, Canada
Chu de Nice-Hopital L'Archet Ii /Id# 208131
Nice, Alpes-Maritimes, France
Hopital Beaujon /ID# 208129
Clichy, Île-de-France Region, France
CHRU Nancy - Hôpitaux de Brabois /ID# 208133
Vandœuvre-lès-Nancy, Meurthe-et-Moselle, France
Charite Universitaetsmedizin Berlin - Campus Mitte /ID# 207570
Berlin, Germany
Universitaetsklinikum Frankfurt /ID# 207569
Frankfurt am Main, Hesse, Germany
Universitaetsklinikum Schleswig-Holstein Campus Kiel /ID# 207571
Kiel, Schleswig-Holstein, Germany
Debreceni Egyetem Klinikai Kozpont /ID# 221952
Debrecen, Hungary
Szegedi Tudomanyegyetem Szent-Gyorgyi Albert Klinikai Kozpont /ID# 221576
Szeged, Csongrád megye, Hungary
Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico /ID# 208504
Milan, Italy
University of Catanzaro /ID# 204546
Catanzaro, Calabria, Italy
Presidio Columbus-Fondazione Policlinico Universitario Agostino Gemelli IRCCS-Un /ID# 204549
Rome, Roma, Italy
Maastricht Universitair Medisch Centrum /ID# 204428
Maastricht, Netherlands
Franciscus Gasthuis & Vlietland /ID# 206976
Rotterdam, Netherlands
Elisabeth Tweesteden Ziekenhuis /ID# 206272
Tilburg, Netherlands
Kyungpook National University Hospital /ID# 209912
Daegu, South Korea
Yeungnam University Medical Center /ID# 210447
Daegu, South Korea
Hospital Santa Creu i Sant Pau /ID# 213259
Barcelona, Spain
Hospital General Universitario Gregorio Maranon /ID# 204504
Madrid, Spain
Hospital Universitario La Paz /ID# 210065
Madrid, Spain
Belfast Health and Social Care Trust /ID# 206744
Belfast, United Kingdom
NHS Greater Glasgow and Clyde /ID# 206574
Glasgow, Scotland, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.